|
Company:
|
AFFIMED N.V. (AFMD)
|
|
Form Type:
|
6-K
|
|
Filing Date:
|
6/23/2022
|
|
CIK:
|
0001608390
|
|
Address:
|
IM NEUENHEIMER FELD 582, 69120
|
|
City, State, Zip:
|
HEIDELBERG, 000000
|
|
Telephone:
|
49-6221-65307
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$2.78
|
Change:
-0.14 (-4.80%)
|
Trade Time:
04:00 PM EST
|
Market Cap:
$405.72M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage immuno-oncology company focused on discovering and
developing highly targeted cancer immunotherapies. Our product candidates
represent an innovative approach to cancer treatment that seeks to harness the
body's own immune defenses to fight tumor cells. The most potent cells of the
human defense arsenal are types of white blood cells called innate immune cells
(Natural Killer cells, or NK cells, and macrophages) and T cells. Leveraging our
fit-for-purpose ROCK® platform, we develop proprietary, next-generation
bispecific and trispecific antibodies, so-called innate cell engagers, which are
designed to direct innate immune cells and establish a bridge to cancer cells.
Our innate cell engagers have the ability to bring innate immune cells into the
proximity of tumor cells and trigger an activation cascade that leads to the
destruction of cancer cells.
|
|
|
|